title: BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice.
authors.affiliation: Department of Hematology, Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
authors.forename: Ciprian
authors.initials: C
authors.lastname: Tomuleasa
authors.forename: Delia
authors.initials: D
authors.lastname: Dima
authors.forename: Ioana
authors.initials: I
authors.lastname: Frinc
authors.forename: Mariana
authors.initials: M
authors.lastname: Patiu
authors.forename: Bobe
authors.initials: B
authors.lastname: Petrushev
authors.forename: Andrei
authors.initials: A
authors.lastname: Cucuianu
authors.forename: Ioana
authors.initials: I
authors.lastname: Berindan-Neagoe
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D009154:Mutation
chemical_list: D016044:Fusion Proteins, bcr-abl